Fennec Pharmaceuticals (FENC) CFO gains 1,558 vested shares

Rhea-AI Filing Summary

Fennec Pharmaceuticals chief financial officer Robert Andrade reported an equity change in the company’s common shares. On January 31, 2026, he acquired 1,558 common shares at a price of $0 per share through the release of restrictions on previously awarded shares.

These shares were released from restriction from awards originally granted on March 31, 2023 and May 16, 2024. Following this vesting event, Andrade directly holds a total of 212,658 common shares of Fennec Pharmaceuticals.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Andrade Robert

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Common shares	1,558	$0.00	--

Holdings After Transaction: Common shares — 212,658 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrade Robert

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NC 27709

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	01/31/2026		A		1,558	A	$0	212,658	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024.

	/s/ Robert Andrade	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Fennec Pharmaceuticals (FENC) report for its CFO?

Fennec Pharmaceuticals reported that CFO Robert Andrade acquired 1,558 common shares. The shares came from the release of restrictions on prior equity awards, rather than an open-market purchase, and were recorded at a price of $0 per share.

How many Fennec (FENC) shares does CFO Robert Andrade own after this Form 4?

After this transaction, CFO Robert Andrade directly owns 212,658 common shares of Fennec Pharmaceuticals. This total reflects the addition of 1,558 shares that were released from restrictions tied to earlier equity awards granted in 2023 and 2024.

What was the price and nature of the FENC shares acquired by the CFO?

The 1,558 Fennec common shares reported were acquired at a stated price of $0 per share. They represent shares released from restriction under prior equity awards, rather than newly purchased stock, indicating a vesting event instead of a market transaction.

When were the underlying Fennec (FENC) share awards originally granted to the CFO?

The shares released to CFO Robert Andrade on January 31, 2026 originated from awards granted on March 31, 2023 and May 16, 2024. The filing notes that the 1,558 shares represent releases from restrictions tied to those earlier grants.

Is the Fennec Pharmaceuticals (FENC) CFO transaction a direct or indirect ownership change?

The Form 4 classifies the transaction as directly owned by CFO Robert Andrade. After the vesting of 1,558 common shares, his beneficial holdings are listed as 212,658 shares under direct ownership, with no indirect ownership entity specified in the filing.